NASDAQ:EYEG - Eyegate Pharmaceuticals Stock Price, Forecast & News

Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) announced its quarterly earnings results on Tuesday, November, 13th. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. The specialty pharmaceutical company had revenue of $0.32 million for the quarter, compared to the consensus estimate of $0.19 million. View Eyegate Pharmaceuticals' Earnings History.

Eyegate Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 6th 2020. View Earnings Estimates for Eyegate Pharmaceuticals.

News stories about EYEG stock have been trending neutral this week, according to InfoTrie. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eyegate Pharmaceuticals earned a news impact score of 0.0 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Eyegate Pharmaceuticals.

Eyegate Pharmaceuticals saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 45,700 shares, a decrease of 55.6% from the January 15th total of 103,000 shares. Based on an average trading volume of 359,100 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.1% of the company's stock are short sold. View Eyegate Pharmaceuticals' Current Options Chain.

Some companies that are related to Eyegate Pharmaceuticals include REDHILL BIOPHAR/S (RDHL), Eton Pharmaceuticals (ETON), Monopar Therapeutics (MNPR), Trevi Therapeutics (TRVI), Chimerix (CMRX), Otonomy (OTIC), Aquestive Therapeutics (AQST), Proteostasis Therapeutics (PTI), Vaccinex (VCNX), Sunesis Pharmaceuticals (SNSS), Enlivex Therapeutics (ENLV), Axovant Gene Therapies (AXGT), Checkpoint Therapeutics (CKPT), TFF Pharmaceuticals (TFFP) and Synlogic (SYBX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyegate Pharmaceuticals investors own include Bausch Health Companies (BHC), MannKind (MNKD), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP), Canopy Growth (CGC), Arca Biopharma (ABIO), Anavex Life Sciences (AVXL) and Novavax (NVAX).

(EYEG) raised $5 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 800,000 shares at a price of $6.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO.

Eyegate Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.83%), Renaissance Technologies LLC (0.81%) and Virtu Financial LLC (0.32%). Company insiders that own Eyegate Pharmaceuticals stock include Armistice Capital Master Fund, Brenda Mann, Morton Goldberg, Sarah Romano and Stephen From. View Institutional Ownership Trends for Eyegate Pharmaceuticals.

EYEG stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Renaissance Technologies LLC and Virtu Financial LLC. View Insider Buying and Selling for Eyegate Pharmaceuticals.

Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EYEG stock can currently be purchased for approximately $6.73.

Eyegate Pharmaceuticals has a market capitalization of $27.25 million and generates $1.65 million in revenue each year. The specialty pharmaceutical company earns $-10,810,000.00 in net income (profit) each year or ($4.50) on an earnings per share basis. Eyegate Pharmaceuticals employs 11 workers across the globe.View Additional Information About Eyegate Pharmaceuticals.

The official website for Eyegate Pharmaceuticals is http://www.eyegatepharma.com/.

Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869.